Abeona Therapeutics (NASDAQ:ABEO) Receives “Buy” Rating from HC Wainwright

Abeona Therapeutics (NASDAQ:ABEO)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $15.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 148.76% from the company’s current price.

A number of other research firms have also recently issued reports on ABEO. StockNews.com raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $18.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, October 29th.

Abeona Therapeutics Stock Up 1.5 %

Abeona Therapeutics stock opened at $6.03 on Monday. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $262.12 million, a PE ratio of -2.22 and a beta of 1.52. The firm’s fifty day moving average is $6.21 and its 200 day moving average is $5.30. Abeona Therapeutics has a 12-month low of $3.05 and a 12-month high of $9.01.

Institutional Investors Weigh In On Abeona Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ABEO. Geode Capital Management LLC boosted its position in shares of Abeona Therapeutics by 21.7% during the third quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock valued at $2,942,000 after buying an additional 83,050 shares during the last quarter. XTX Topco Ltd bought a new position in Abeona Therapeutics during the 3rd quarter valued at $160,000. Jane Street Group LLC purchased a new position in Abeona Therapeutics during the 3rd quarter worth $84,000. Western Standard LLC grew its stake in shares of Abeona Therapeutics by 7.0% in the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock worth $10,732,000 after acquiring an additional 110,998 shares in the last quarter. Finally, Citigroup Inc. grew its stake in shares of Abeona Therapeutics by 10.1% in the 3rd quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock worth $3,897,000 after acquiring an additional 56,332 shares in the last quarter. 80.56% of the stock is owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.